Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial

Hisatomi Arima, Christophe Tzourio, Ken Butcher, Craig Anderson, Marie Germaine Bousser, Kennedy R. Lees, John L. Reid, Teruo Omae, Mark Woodward, Stephen MacMahon, John Chalmers

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND PURPOSE - The relationship between baseline and recurrent vascular events may be important in the targeting of secondary prevention strategies. We examined the relationship between initial event and various types of further vascular outcomes and associated effects of blood pressure (BP)-lowering. METHODS - Subsidiary analyses of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial, a randomized, placebo-controlled trial that established the benefits of BP-lowering in 6105 patients (mean age 64 years, 30% female) with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, plus indapamide in those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). RESULTS - Stroke subtypes and coronary events were associated with 1.5- to 6.6-fold greater risk of recurrence of the same event (hazard ratios, 1.51 to 6.64; P=0.1 for large artery infarction, P

Original languageEnglish (US)
Pages (from-to)1497-1502
Number of pages6
JournalStroke
Volume37
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Perindopril
Blood Vessels
Stroke
Placebos
Indapamide
Blood Pressure
Cerebrovascular Disorders
Secondary Prevention
Diuretics
Infarction
Randomized Controlled Trials
Arteries
Recurrence
Therapeutics

Keywords

  • Antihypertensive agents
  • Myocardial infarction
  • Randomized controlled trials
  • Recurrence
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Arima, H., Tzourio, C., Butcher, K., Anderson, C., Bousser, M. G., Lees, K. R., ... Chalmers, J. (2006). Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke, 37(6), 1497-1502. https://doi.org/10.1161/01.STR.0000221212.36860.c9

Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. / Arima, Hisatomi; Tzourio, Christophe; Butcher, Ken; Anderson, Craig; Bousser, Marie Germaine; Lees, Kennedy R.; Reid, John L.; Omae, Teruo; Woodward, Mark; MacMahon, Stephen; Chalmers, John.

In: Stroke, Vol. 37, No. 6, 06.2006, p. 1497-1502.

Research output: Contribution to journalArticle

Arima, H, Tzourio, C, Butcher, K, Anderson, C, Bousser, MG, Lees, KR, Reid, JL, Omae, T, Woodward, M, MacMahon, S & Chalmers, J 2006, 'Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial', Stroke, vol. 37, no. 6, pp. 1497-1502. https://doi.org/10.1161/01.STR.0000221212.36860.c9
Arima H, Tzourio C, Butcher K, Anderson C, Bousser MG, Lees KR et al. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke. 2006 Jun;37(6):1497-1502. https://doi.org/10.1161/01.STR.0000221212.36860.c9
Arima, Hisatomi ; Tzourio, Christophe ; Butcher, Ken ; Anderson, Craig ; Bousser, Marie Germaine ; Lees, Kennedy R. ; Reid, John L. ; Omae, Teruo ; Woodward, Mark ; MacMahon, Stephen ; Chalmers, John. / Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. In: Stroke. 2006 ; Vol. 37, No. 6. pp. 1497-1502.
@article{04ddbb9da1614b318cf52c4ec92bca85,
title = "Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial",
abstract = "BACKGROUND AND PURPOSE - The relationship between baseline and recurrent vascular events may be important in the targeting of secondary prevention strategies. We examined the relationship between initial event and various types of further vascular outcomes and associated effects of blood pressure (BP)-lowering. METHODS - Subsidiary analyses of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial, a randomized, placebo-controlled trial that established the benefits of BP-lowering in 6105 patients (mean age 64 years, 30{\%} female) with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, plus indapamide in those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). RESULTS - Stroke subtypes and coronary events were associated with 1.5- to 6.6-fold greater risk of recurrence of the same event (hazard ratios, 1.51 to 6.64; P=0.1 for large artery infarction, P",
keywords = "Antihypertensive agents, Myocardial infarction, Randomized controlled trials, Recurrence, Stroke",
author = "Hisatomi Arima and Christophe Tzourio and Ken Butcher and Craig Anderson and Bousser, {Marie Germaine} and Lees, {Kennedy R.} and Reid, {John L.} and Teruo Omae and Mark Woodward and Stephen MacMahon and John Chalmers",
year = "2006",
month = "6",
doi = "10.1161/01.STR.0000221212.36860.c9",
language = "English (US)",
volume = "37",
pages = "1497--1502",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial

AU - Arima, Hisatomi

AU - Tzourio, Christophe

AU - Butcher, Ken

AU - Anderson, Craig

AU - Bousser, Marie Germaine

AU - Lees, Kennedy R.

AU - Reid, John L.

AU - Omae, Teruo

AU - Woodward, Mark

AU - MacMahon, Stephen

AU - Chalmers, John

PY - 2006/6

Y1 - 2006/6

N2 - BACKGROUND AND PURPOSE - The relationship between baseline and recurrent vascular events may be important in the targeting of secondary prevention strategies. We examined the relationship between initial event and various types of further vascular outcomes and associated effects of blood pressure (BP)-lowering. METHODS - Subsidiary analyses of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial, a randomized, placebo-controlled trial that established the benefits of BP-lowering in 6105 patients (mean age 64 years, 30% female) with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, plus indapamide in those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). RESULTS - Stroke subtypes and coronary events were associated with 1.5- to 6.6-fold greater risk of recurrence of the same event (hazard ratios, 1.51 to 6.64; P=0.1 for large artery infarction, P

AB - BACKGROUND AND PURPOSE - The relationship between baseline and recurrent vascular events may be important in the targeting of secondary prevention strategies. We examined the relationship between initial event and various types of further vascular outcomes and associated effects of blood pressure (BP)-lowering. METHODS - Subsidiary analyses of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial, a randomized, placebo-controlled trial that established the benefits of BP-lowering in 6105 patients (mean age 64 years, 30% female) with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, plus indapamide in those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). RESULTS - Stroke subtypes and coronary events were associated with 1.5- to 6.6-fold greater risk of recurrence of the same event (hazard ratios, 1.51 to 6.64; P=0.1 for large artery infarction, P

KW - Antihypertensive agents

KW - Myocardial infarction

KW - Randomized controlled trials

KW - Recurrence

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=33745164898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745164898&partnerID=8YFLogxK

U2 - 10.1161/01.STR.0000221212.36860.c9

DO - 10.1161/01.STR.0000221212.36860.c9

M3 - Article

C2 - 16627794

AN - SCOPUS:33745164898

VL - 37

SP - 1497

EP - 1502

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 6

ER -